Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity

被引:126
作者
Tapia, C
Kutzner, H
Mentzel, T
Savic, S
Baumhoer, D
Glatz, K
机构
[1] Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland
[2] Dermatohistopathol Gemeinschaftsalabor, Friedrichshafen, Germany
关键词
immunohistochemistry; MPM2; phosphohistone-H3; Ser28 (PHH3); mitosis count;
D O I
10.1097/01.pas.0000183572.94140.43
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Mitotic figure (MF) counting is important in the evaluation of many tumor types. Inadequate fixation, crush artefacts, the presence of many apoptoses, or the rarity of MFs in a given lesion can make the determination of the mitotic index a very time-consuming or even impossible task, especially for novices. We evaluated the potential of the two commercially available mitotic markers MPM-2 and Phospho-Histone H3 Ser28 (PHH3) for improving mitotic counting. Formalin-fixed tissue of 1 lymphoma, 19 epithelial, 25 mesenchymal, and 10 melanocytic tumors was immunohistochemically stained with both antibodies. Mitotic counts of each tumor sample were determined by a pathologist and three residents in the hernatoxylin and eosin and in both immunohistochemical stainings. Because of the higher sensitivity of the immunohistochemical stainings for MFs, average mitotic counts per 10 HPF were higher with MPM-2 (11.0) and PHH3 (10.1) than with hernatoxylin and eosin (5.9) staining. The precise distinction of MFs from apoptoses and the visualization of the distribution of MFs uncovering mitotic hotspots, even at low magnification, turned out to be major advantages of both mitotic markers. In addition, the average time needed to establish the mitotic count was reduced by 40.3% with MPM-2 and by 50.4% with PHH3. MPM-2 and PHH3 were subjectively rated by all pathologists involved in this study to be very helpful in mitotic counting, especially in melanocytic and mesenchymal lesions but less so in epithelial tumors. Both markers have hence been successfully introduced in our laboratory for the routine assessment of MFs in melanocytic and mesenchymal tumors.
引用
收藏
页码:83 / 89
页数:7
相关论文
共 51 条
[1]   Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma - An analysis of 3661 patients from a single center [J].
Azzola, MF ;
Shaw, HM ;
Thompson, JF ;
Soong, SJ ;
Scolyer, RA ;
Watson, GF ;
Colman, MH ;
Zhang, YT .
CANCER, 2003, 97 (06) :1488-1498
[2]   MITOSIS COUNTING IN TUMORS [J].
BAAK, JPA .
HUMAN PATHOLOGY, 1990, 21 (07) :683-685
[3]  
Belien JAM, 1997, CYTOMETRY, V28, P135, DOI 10.1002/(SICI)1097-0320(19970601)28:2<135::AID-CYTO6>3.3.CO
[4]  
2-R
[5]   PROBLEMATIC UTERINE SMOOTH-MUSCLE NEOPLASMS - A CLINICOPATHOLOGICAL STUDY OF 213 CASES [J].
BELL, SW ;
KEMPSON, RL ;
HENDRICKSON, MR .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1994, 18 (06) :535-558
[6]   Immunocytochemical assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium [J].
Brenner, RM ;
Slayden, OD ;
Rodgers, WH ;
Critchley, HOD ;
Carroll, R ;
Nie, XJ ;
Mah, K .
HUMAN REPRODUCTION, 2003, 18 (06) :1185-1193
[7]  
COINDRE JM, 1986, CANCER, V58, P306, DOI 10.1002/1097-0142(19860715)58:2<306::AID-CNCR2820580216>3.0.CO
[8]  
2-7
[9]  
Coindre JM, 2001, CANCER-AM CANCER SOC, V91, P1914, DOI 10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO
[10]  
2-3